The introduction of a third CDK4/6 inhibitor does not change the cost-effectiveness profile in first and subsequent-lines after progression or relapse during previous endocrine therapy in patients with hormone receptor positive (HR+)/human epidermal
| Image |  |
|---|---|
| Description | scientific article published on 23 June 2020 |
| Author/s |
author: Jacopo Giuliani |
| Publication date | June 23, 2020 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |